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Background -New rapid diagnostic techniques offer the opportunity of early diagnosis of human cytomegalovirus (CMV) infection in immunocompromised patients at risk ofdeveloping CMV disease. The use of human CMV antigenaemia as a predictorofclinical CMV infection and disease in lung and heart transplant recipients was studied prospectively. Methods -Twenty three heart and nine lung transplant recipients who survived 40 days were observed by standard CMV surveillance with serological testing, culture, and by sequential testing for CMV antigenaemia. CMV antigenaemia testing is a rapid and quantifiable technique in which a viral lower matrix protein is detected in cytospin preparations of peripheral blood polymorphonuclear leucocytes (PMNLs) by immunofluorescent staining. Results -Eleven patients developed CMV infection and five developed CMV disease (four pneumonitis, one duodenitis). These clinical events occurred at a median of 65 days following transplantation. CMV antigenaemia occurred in 17 patients at a median of 35 days following transplantation. Detection of CMV antigenaemia had a sensitivity of 100%, a specificity of 93 7%, and a positive predictive value of94-1% for CMV related illness. CMV antigenaemia was positive at a significant interval before the clinical event. High levels of CMV antigenaemia (>50 CMV antigen positive cells/2 x IO05PMNLs) occurred in 11 patients and five of these developed disease. CMV antigenaemia of >50 CMV antigen positive cells/2 x 105 PMNLs had a positive predictive value of45'5% for disease but a negative predictive value of 100%. Patients with disease had higher levels of antigenaemia than those without disease. Conclusions-CMV antigenaemia is a rapid diagnostic technique which can identify patients likely to develop CMV disease, potentially allowing early treatment.
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Human cytomegalovirus (CMV) infection causes significant morbidity and mortality in lung and heart transplant recipients. In addition to the direct effects of infection such as CMV pneumonitis, the infection is also associated with direct immunopathological effects including superinfection from bacterial and fungal organisms,l graft rejection and failure,2 3 and possibly obliterative bronchiolitis.4 These serious problems have prompted the use of antiviral prophylaxis in both lung5 and heart6 transplant recipients, but with questionable advantage because of the high cost and the morbidity of current prophylactic regimens and because the benefit is not yet substantial. 67 The clinical problems caused by CMV infection are compounded by the fact that the standard diagnostic techniques of serology and culture often allow only a retrospective diagnosis to be made, prompting the need for histological confirmation of CMV disease. New rapid diagnostic techniques might allow the clinician to predict which patients are at greatest risk from CMV, allowing early targeted treatment. CMV antigenaemia testing, which involves the detection of CMV lower matrix phosphoprotein in peripheral blood polymorphonuclear leucocytes (PMNLs) using a monoclonal antibody, is one such technique and has the advantage of being rapid and quantifiable.89 The purpose of this study was to assess the feasibility and clinical utility of serial monitoring of CMV antigenaemia for predicting illness and pneumonitis in thoracic transplant recipients. (fig 2) .
Twelve of the 15 CMV antigen negative patients were D -R-(table 2). The remaining three were "high risk" patients; two D +R-recipients (R +) whose donors were CMV sero-heart transplant recipients who received impositive (D+). Twelve seronegative recipients munoglobulin prophylaxis and one D-R+ were matched with seronegative donors lung transplant recipient who received no pro-(D-R-). Four seronegative recipients re-phylaxis ( The detection of human CMV antigenaemia in peripheral blood PMNLs is a rapid and quantifiable technique that has been used for the monitoring of CMV infection in heart trans- Table 4 Serological results, infection, and quantity of antigenaemia plant recipients89 and for the early diagnosis of CMV infection in renal transplant recipients."9
In our patients CMV antigenaemia had a sensitivity of 100% and a specificity of 93-7% for infection as defined by conventional diagnostic techniques (CMV specific IgM, positive bronchoalveolar lavage DEAFF test). One patient (patient 1, table 4) with pyrexia in association with peripheral blood antigenaemia was not defined as having a CMV related event as he failed to demonstrate evidence ofinfection using conventional diagnostic techniques. In view of the strict end point definitions we may have underestimated the specificity of CMV antigenaemia.
In addition to high sensitivity and specificity for CMV infection, antigenaemia offers two further advantages. Firstly, it occurs significantly before the onset of clinical symptoms and serological changes. Secondly, measurement of levels of antigenaemia may allow the clinician to predict patients most likely to develop CMV disease.
Invasive diagnostic techniques are currently needed to confirm or exclude CMV disease, but quantifiable techniques such as CMV antigenaemia could allow clinicians to be more selective as to which patients are subjected to biopsy or treated blind with antiviral therapy. High level antigenaemia (>50 cells/2 x 105 PMNLs) had a positive predictive value of 45% and a negative predictive value of 100%. The importance ofthe high negative predictive value is emphasised by the absence of CMV antigenaemia in two seronegative heart transplant recipients whose donors were seropositive and one seropositive lung recipient whose donor was seronegative (table 2) . These three patients were at high risk of developing CMV related illness and the heart transplant recipients received immunoglobulin prophylaxis. As neither of the heart recipients subsequently developed CMV infection it is possible that the donor serological results may have been falsely positive. The clinical application of CMV antigenaemia in these cases would have allowed the antiviral therapy to be withheld in the absence of viraemia, thereby reducing drug costs and morbidity. The 
